drugset
Drugs / Leuprolide
last change 3 days ago re-read 2 minutes ago

Leuprolide

also known as leuprolide acetate · Leuprorelin · Lupron · leuprorelin acetate · Eligard · Lupron Depot · Lucrin · CKD-841 · +36 more

Other / unclassified

Developed for
prostate cancer · central precocious puberty · prostate adenocarcinoma · breast cancer · endometriosis · infertility disorder · female breast carcinoma · prostate carcinoma
+61 more · prostate neoplasm · Alzheimer disease · invasive breast carcinoma · metastatic prostate carcinoma · ovarian hyperstimulation syndrome · plasma cell myeloma · polycystic ovary syndrome · salivary gland carcinoma · adenomyosis · breast carcinoma · female infertility · HER2 positive breast carcinoma · Hodgkins lymphoma · hypogonadism · leiomyoma · pedophilia · pregnancy disorder · primary ovarian failure · acanthosis nigricans · amenorrhea · amyotrophic lateral sclerosis · atypical endometrial hyperplasia · breast mucinous carcinoma · breast neoplasm · bulbospinal muscular atrophy · cancer · cognitive impairment with or without cerebellar ataxia · endometrial cancer · endometrial carcinoma · endometrial endometrioid adenocarcinoma · endometrium neoplasm · estrogen-receptor positive breast cancer · fibrolamellar hepatocellular carcinoma · hemangioma · Her2-receptor negative breast cancer · hormone receptor-positive breast cancer · hypothyroidism · inflammatory breast carcinoma · invasive tubular breast carcinoma · isolated short stature · liver disorder · lymph node cancer · male breast carcinoma · mantle cell lymphoma · melanoma · metastatic malignant neoplasm · metastatic neoplasm · non-small cell lung carcinoma · obstructive sleep apnea syndrome · ovarian granulosa cell tumor · paraphilic disorder · pelvis syndrome · premenstrual tension · prostate disorder · prostate neuroendocrine neoplasm · triple-negative breast carcinoma · uterine corpus leiomyoma · benign neoplasm of corpus uteri · dysmenorrhea · idiopathic central precocious puberty · ovarian endometriosis
Investigated by
National Cancer Institute (NCI) · M.D. Anderson Cancer Center · Abbott · Takeda · Dana-Farber Cancer Institute · Memorial Sloan Kettering Cancer Center
+234 more · Radiation Therapy Oncology Group · Astellas Pharma Inc · Fudan University · NRG Oncology · Pfizer · Eastern Cooperative Oncology Group · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Foresee Pharmaceuticals Co., Ltd. · Mayo Clinic · National Institute of Mental Health (NIMH) · National Institute on Aging (NIA) · TAP Pharmaceutical Products Inc. · University of Chicago · University of Colorado, Denver · Weill Medical College of Cornell University · Alliance for Clinical Trials in Oncology · Bayer · Baylor College of Medicine · Changchun GeneScience Pharmaceutical Co., Ltd. · GP-Pharm · Merck Sharp & Dohme LLC · National Center for Research Resources (NCRR) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Novartis Pharmaceuticals · SWOG Cancer Research Network · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · University of Washington · Beth Israel Deaconess Medical Center · Brigham and Women's Hospital · Bristol-Myers Squibb · Cancer and Leukemia Group B · Chong Kun Dang Pharmaceutical · City of Hope Medical Center · Daewoong Pharmaceutical Co. LTD. · Eli Lilly and Company · Emory University · Enteris BioPharma Inc. · European Organisation for Research and Treatment of Cancer - EORTC · Genentech, Inc. · HanAll BioPharma Co., Ltd. · Johns Hopkins University · Massachusetts General Hospital · NYU Langone Health · National Comprehensive Cancer Network · National Taiwan University Hospital · Oakwood Laboratories, LLC · Peking Union Medical College Hospital · Proton Collaborative Group · Scottish Cancer Therapy Network · Severance Hospital · Sumitomo Pharma America, Inc. · Syneos Health · Tolmar Inc. · Tolmar Pharmaceuticals · University College, London · University Medical Center Groningen · University of California, San Francisco · University of Michigan · University of North Carolina, Chapel Hill · University of Texas Southwestern Medical Center · Voyager Pharmaceutical Corporation · AbbVie · AbbVie · Alkü Alanya Education and Research Hospital · Antalya IVF · Assistance Publique - Hôpitaux de Paris · Astellas Pharma Europe Ltd. · Astellas Pharma Inc · Astellas Pharma US, Inc. · AstraZeneca · Baptist Health South Florida · Beijing Chao Yang Hospital · Bharat Serums and Vaccines Limited · Blue Earth Diagnostics · all 240 on the full record

Regulatory milestones approvals, filings & regulatory actions · 14 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (4) US (FDA) LUPRON DEPOT-PED KIT — 2011-08-15 – 2025-05-22 fda.gov ↗
Label expansion US (FDA) ELIGARD KIT — 2023-07-20 fda.gov ↗
Label expansion US (FDA) LEUPROLIDE ACETATE FOR DEPOT SUSPENSION — 2023-02-28 fda.gov ↗
Approved EU (EMA) Camcevi — 2022-05-24 europa.eu ↗
Label expansions (6) US (FDA) LUPRON DEPOT — 1997-05-30 – 2022-04-18 fda.gov ↗
Approved US (FDA) LUPRON — 1985-04-09 fda.gov ↗

Trials 220 · started per year

today
US approved 1985
EU approved 2022
1
1
2
4
2
2
3
1
4
4
2
10
4
5
7
7
9
8
2
11
13
8
12
8
11
12
7
3
7
7
7
13
8
6
7
19851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 03 trials
Phase 0 NCT03511196 Sep 2018 → Jun 2022 overdue prostate adenocarcinoma H. Lee Moffitt Cancer Center and Research Institute Active not recruiting No outcome recorded
Phase 0 NCT01422096 Jun → Jul 2018 obesity disorder, polycystic ovary syndrome University of Virginia Withdrawn No outcome recorded
Phase 0 NCT00734279 Mar 2006 → Nov 2010 delayed puberty, self-limited, precocious puberty University of Utah Completed No outcome recorded
Phase 111 trials
Phase 1 NCT04840745 Apr → Oct 2021 precocious puberty Chong Kun Dang Pharmaceutical Unknown No outcome recorded
Phase 1 NCT04783636 Mar → Jul 2021 prostate cancer Peptron, Inc. Unknown No outcome recorded
Phase 1 NCT04760691 Mar 2021 → Mar 2025 HIV infectious disease Johns Hopkins University Completed No outcome recorded
Phase 1 NCT03233932 Apr 2016 → Jul 2017 — Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT02448459 May 2015 → Mar 2016 infertility disorder University of Sao Paulo Completed No outcome recorded
Phase 1 NCT02023463 Apr 2014 → Jul 2017 overdue prostate adenocarcinoma Thomas Jefferson University Active not recruiting No outcome recorded
Phase 1 NCT02064036 Jun 2013 → Dec 2020 prostate adenocarcinoma University of California, Davis Completed No outcome recorded
Phase 1 NCT01160328 Jun 2010 → Jan 2013 obesity disorder Mayo Clinic Completed No outcome recorded
Phase 1 NCT00379626 Aug 2003 → Aug 2008 paraphilic disorder Norwegian University of Science and Technology Terminated No outcome recorded
Phase 1 NCT02911350 May 2000 → Dec 2016 prostate cancer NYU Langone Health Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT02990845 Sep 2017 → Aug 2022 breast carcinoma National Taiwan University Hospital Terminated No outcome recorded
Phase 1/2 NCT00669162 Aug 2012 → Aug 2016 prostate cancer University of Kansas Medical Center Completed No outcome recorded
Phase 1/2 NCT00653757 Mar 2002 → Dec 2006 prostate cancer Mayo Clinic Completed No outcome recorded
Phase 292 trials
Phase 2 NCT07610733 Jun 2026 → Sep 2027 expected breast cancer Fudan University Not yet recruiting No outcome recorded
Phase 2 NCT07027124 May 2026 → Dec 2027 expected prostate cancer Icahn School of Medicine at Mount Sinai Recruiting No outcome recorded
Phase 2 NCT07455903 Apr 2026 → Oct 2029 expected prostate carcinoma Baptist Health South Florida Recruiting No outcome recorded
Phase 2 NCT06654336 Mar 2026 → Apr 2031 expected prostate adenocarcinoma Ontario Clinical Oncology Group (OCOG) Recruiting No outcome recorded
Phase 2 NCT07158021 Jan 2026 → Jan 2028 expected female breast carcinoma, invasive breast carcinoma University of Michigan Rogel Cancer Center Recruiting No outcome recorded
Phase 2 NCT07313241 Nov 2025 → Nov 2030 expected prostate cancer University of Texas Southwestern Medical Center Recruiting No outcome recorded
Phase 2 NCT07159451 Oct 2025 → Jan 2027 expected breast cancer Gustave Roussy, Cancer Campus, Grand Paris Recruiting No outcome recorded
Phase 2 NCT07179939 Sep 2025 → Dec 2030 expected HER2 positive breast carcinoma Fudan University Not yet recruiting No outcome recorded
Phase 2 NCT06225284 Aug 2024 → Dec 2026 expected triple-negative breast carcinoma National Taiwan University Hospital Recruiting No outcome recorded
Phase 2 NCT06330805 Aug 2024 → Dec 2027 expected prostate adenocarcinoma Ohio State University Comprehensive Cancer Center Recruiting No outcome recorded
Phase 2/34 trials
Phase 2/3 NCT05316935 Jul 2022 → Mar 2026 overdue atypical endometrial hyperplasia, endometrium neoplasm, progesterone resistance Xiaojun Chen Recruiting No outcome recorded
Phase 2/3 NCT02221999 Sep 2013 → Jan 2019 overdue breast mucinous carcinoma, inflammatory breast carcinoma, invasive tubular breast carcinoma RenJi Hospital Active not recruiting No outcome recorded
Phase 2/3 NCT01603420 Jul 2012 → May 2014 prostate cancer Proton Collaborative Group Terminated No outcome recorded
Phase 2/3 NCT00220350 Oct 2001 → Aug 2005 pedophilia Schober, Justine, M.D. Unknown No outcome recorded
Phase 354 trials
Phase 3 NCT06855589 Mar 2025 → Mar 2033 expected prostate adenocarcinoma Charles LeMoyne Hospital Not yet recruiting No outcome recorded
Phase 3 NCT06650579 Jan 2025 → Jul 2029 expected prostate carcinoma Emory University Recruiting No outcome recorded
Phase 3 NCT06449027 Aug 2024 → Nov 2025 overdue breast carcinoma Changchun GeneScience Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded
Phase 3 NCT06490328 May 2024 → May 2025 overdue prostate cancer Dongkook Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT06025409 Aug 2023 → Feb 2025 central precocious puberty Daewoong Pharmaceutical Co. LTD. Unknown No outcome recorded
Phase 3 NCT05493709 Jun 2023 → Dec 2025 central precocious puberty Foresee Pharmaceuticals Co., Ltd. Completed No outcome recorded
Phase 3 NCT05169112 Mar 2023 → Nov 2026 expected prostate cancer Ottawa Hospital Research Institute Recruiting No outcome recorded
Phase 3 NCT06984159 Jul 2022 → Nov 2023 prostate cancer Changchun GeneScience Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 3 NCT05352178 Apr 2022 → Apr 2027 expected metastatic malignant neoplasm, metastatic prostate carcinoma Universitaire Ziekenhuizen KU Leuven Recruiting No outcome recorded
Phase 3 NCT04914195 Jul 2021 → Sep 2022 prostate adenocarcinoma Bharat Serums and Vaccines Limited Completed No outcome recorded
Phase 431 trials
Phase 4 NCT07710430 Aug 2026 → Aug 2029 expected central precocious puberty LG Chem Not yet recruiting No outcome recorded
Phase 4 NCT06627530 Feb 2025 → Mar 2026 overdue prostate cancer Brazilian Clinical Research Institute Active not recruiting No outcome recorded
Phase 4 NCT06926933 Dec 2024 → Jun 2026 overdue — HanAll BioPharma Co., Ltd. Active not recruiting No outcome recorded
Phase 4 NCT05937490 Mar 2023 → Mar 2025 adenomyosis University Hospital of Modena Unknown No outcome recorded
Phase 4 NCT05341115 Mar 2023 → Dec 2024 central precocious puberty Takeda Completed No outcome recorded
Phase 4 NCT05333328 Feb 2023 → Jan 2031 expected Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer Gangnam Severance Hospital Recruiting No outcome recorded
Phase 4 NCT03946722 Aug 2020 → Aug 2023 adenomyosis University College, London Unknown No outcome recorded
Phase 4 NCT04248621 Jan 2020 → Apr 2022 prostate neoplasm Wonju Severance Christian Hospital Unknown No outcome recorded
Phase 4 NCT05304169 Nov 2017 → Jun 2018 prostate cancer Zodiac Produtos Farmaceuticos S.A. Completed No outcome recorded
Phase 4 NCT03047330 Jul 2017 → Aug 2022 — Brigham and Women's Hospital Completed No outcome recorded
Phase not applicable22 trials
— NCT07444983 Feb 2026 → Feb 2027 expected prostate adenocarcinoma Fujian Medical University Union Hospital Not yet recruiting No outcome recorded
— NCT06512207 Dec 2023 → Dec 2025 overdue non-small cell lung carcinoma Jinzhou Medical University Recruiting No outcome recorded
— NCT05206682 May 2023 → Apr 2027 expected — Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Recruiting No outcome recorded
— NCT05667428 Mar 2023 → Oct 2025 disease related to hematopoietic stem cell transplant, primary ovarian failure First Affiliated Hospital Xi'an Jiaotong University Unknown No outcome recorded
— NCT04192812 Dec 2020 → Dec 2021 central precocious puberty, leiomyoma Alkü Alanya Education and Research Hospital Unknown No outcome recorded
— NCT02927392 Mar 2017 → May 2023 obesity disorder University of Colorado, Denver Completed No outcome recorded
— NCT02979886 Jan 2017 → Jun 2019 female infertility Miao benyu Unknown No outcome recorded
— NCT05945407 Aug 2016 → Dec 2023 overdue endometrial cancer, endometrial endometrioid adenocarcinoma Peking University People's Hospital Recruiting No outcome recorded
— NCT02238431 Dec 2014 → May 2016 pregnancy disorder Antalya IVF Withdrawn No outcome recorded
— NCT02114645 Apr 2014 → Feb 2015 infertility disorder Zekai Tahir Burak Women's Health Research and Education Hospital Unknown No outcome recorded
Also used as a comparator or background therapy in 204 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 04 trials
Phase 0 NCT07389174 Background Feb 2026 → Jan 2027 expected prostate adenocarcinoma Shanghai Changzheng Hospital Not yet recruiting No outcome recorded
Phase 0 NCT07389187 Background Feb → Dec 2026 expected castration-resistant prostate carcinoma Shanghai Changzheng Hospital Not yet recruiting No outcome recorded
Phase 0 NCT04445025 Comparator Sep 2020 → Sep 2024 endometriosis, infertility disorder Colorado Center for Reproductive Medicine Completed No outcome recorded
Phase 0 NCT01763541 Background Jun 2014 → Feb 2016 hypertensive disorder Massachusetts General Hospital Withdrawn No outcome recorded
Phase 113 trials
Phase 1 NCT06305598 Background Dec 2024 → Dec 2029 expected castration-resistant prostate carcinoma, metastatic prostate carcinoma Roswell Park Cancer Institute Recruiting No outcome recorded
Phase 1 NCT05617885 Background Aug 2023 → Jul 2025 metastatic prostate carcinoma Praful Ravi, MB BCHir, MRCP Completed No outcome recorded
Phase 1 NCT03332797 Background Nov 2017 → Jul 2027 expected breast cancer Genentech, Inc. Active not recruiting No outcome recorded
Phase 1 NCT03029533 Comparator Feb → Nov 2017 prostate cancer Daewoong Pharmaceutical Co. LTD. Unknown No outcome recorded
Phase 1 NCT02920359 Background Nov → Dec 2016 — Parc de Salut Mar Completed No outcome recorded
Phase 1/29 trials
Phase 1/2 NCT07596212 Background Jul 2026 → Jul 2028 expected hormone receptor-positive breast cancer, hypoactive sexual desire disorder University of Illinois at Chicago Not yet recruiting No outcome recorded
Phase 1/2 NCT04194554 Background Nov 2020 → May 2027 expected prostate cancer University of Michigan Rogel Cancer Center Active not recruiting No outcome recorded
Phase 1/2 NCT01132404 Comparator Nov 2010 → Sep 2011 prostate cancer Millennium Pharmaceuticals, Inc. Terminated No outcome recorded
Phase 1/2 NCT01163084 Background Jul 2010 → Jun 2012 prostate adenocarcinoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1/2 NCT00924807 Background Sep 2008 → Dec 2013 prostate cancer Beth Israel Medical Center Terminated No outcome recorded
Phase 285 trials
Phase 2 NCT07650240 Background Jul 2026 → Dec 2030 expected metastatic prostate carcinoma, prostate adenocarcinoma Mayo Clinic Not yet recruiting No outcome recorded
Phase 2 NCT07142551 Background Mar 2026 → Jun 2030 expected castration-resistant prostate carcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting No outcome recorded
Phase 2 NCT06849947 Comparator Feb 2026 → Jun 2031 expected breast carcinoma Yeon Hee Park Not yet recruiting No outcome recorded
Phase 2 NCT07268794 Background Nov 2025 → Apr 2027 expected metastatic prostate carcinoma, prostate adenocarcinoma Fudan University Not yet recruiting No outcome recorded
Phase 2 NCT06922318 Background Aug 2025 → Aug 2031 expected castration-resistant prostate carcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting No outcome recorded
Phase 2/34 trials
Phase 2/3 NCT06282588 Background Dec 2023 → Jul 2030 expected prostate cancer Cancer Research Antwerp Recruiting No outcome recorded
Phase 2/3 NCT04787744 Background Jul 2021 → Sep 2026 expected metastatic prostate carcinoma VA Office of Research and Development Recruiting No outcome recorded
Phase 2/3 NCT03070886 Background Apr 2017 → Oct 2025 prostate adenocarcinoma NRG Oncology Completed No outcome recorded
Phase 2/3 NCT02685397 Background Oct 2016 → Apr 2027 expected castration-resistant prostate carcinoma Sir Mortimer B. Davis - Jewish General Hospital Active not recruiting No outcome recorded
Phase 355 trials
Phase 3 NCT07477626 Background Mar 2026 → Dec 2033 expected metastatic malignant neoplasm in the lymph nodes, prostate cancer Sun Yat-sen University Recruiting No outcome recorded
Phase 3 NCT07015268 Comparator Jun 2025 → Nov 2027 expected endometriosis Kissei Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded
Phase 3 NCT05827081 Background Feb 2024 → Sep 2029 expected female breast carcinoma Novartis Pharmaceuticals Recruiting No outcome recorded
Phase 3 NCT05879926 Comparator Oct 2023 → Jan 2032 expected breast cancer NRG Oncology Recruiting No outcome recorded
Phase 3 NCT06145438 Comparator Sep 2023 → Aug 2024 ovarian endometriosis Universitas Diponegoro Completed No outcome recorded
Phase 421 trials
Phase 4 NCT05700903 Comparator Sep 2023 → Jul 2025 dysautonomia, hypertensive disorder, kidney disorder, prostate cancer University of Colorado, Denver Completed No outcome recorded
Phase 4 NCT02393482 Comparator Jun → Dec 2021 amenorrhea, endometriosis University of Cagliari Unknown No outcome recorded
Phase 4 NCT04094467 Comparator Dec 2019 → Oct 2020 polycystic ovary syndrome Assiut University Unknown No outcome recorded
Phase 4 NCT03963752 Comparator Aug 2019 → Aug 2022 idiopathic central precocious puberty Children's Hospital of Fudan University Completed No outcome recorded
Phase 4 NCT03683043 Comparator Sep 2018 → Sep 2019 — Cairo University Unknown No outcome recorded
Phase not applicable13 trials
— NCT07142967 Background Aug 2025 → Aug 2028 expected prostate cancer NYU Langone Health Recruiting No outcome recorded
— NCT05628363 Background Jan 2023 → Oct 2025 overdue prostate cancer Washington University School of Medicine Active not recruiting No outcome recorded
— NCT05437471 Comparator Jan 2020 → Dec 2021 pregnancy loss, recurrent, 4 Universiti Kebangsaan Malaysia Medical Centre Completed No outcome recorded
— NCT03662958 Comparator Aug → Oct 2018 prostate cancer Lee's Pharmaceutical Limited Unknown No outcome recorded
— NCT04500743 Comparator Aug 2018 → Oct 2019 endometriosis National Research Centre, Egypt Completed No outcome recorded

Press releases naming this drug 7 releases

DateIssuerRelease
2025-10-19 Pfizer XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer pfizer.com ↗
2025-07-10 Pfizer XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence pfizer.com ↗
2023-04-29 Pfizer XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide pfizer.com ↗
2023-03-16 Pfizer Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer pfizer.com ↗
2015-12-15 Takeda Takeda's "Leuplin ® PRO for Injection Kit 22.5 mg" Now Available for the Treatment of Prostate Cancer/Premenopausal Breast Cancer in Japan takeda.com ↗
2015-09-28 Takeda Takeda Obtained New Drug Application Approval of "Leuplin ® PRO for injection kit 22.5 mg" in Japan for the Treatment of Prostate Cancer and Premenopausal Breast Cancer takeda.com ↗
2014-09-05 Takeda Takeda Submits a New Drug Application for Leuplin ® 6 Month Depot in Japan for the Treatment of Prostate Cancer and Premenopausal Breast Cancer takeda.com ↗

Evidence & citations 48 cited values

Every value below carries the sentence it was read from. 427 sources stand behind the page.

FieldValueCited text
Known as Leuprolide “All patients receive neoadjuvant androgen-deprivation therapy comprising bicalutamide orally (PO) once daily or flutamide PO thrice daily for 4-6 months, and luteinizing...” NCT01368588 ↗
162

“Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the...” NCT04557059 ↗

“LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3...” NCT01088529 ↗

“one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily...” NCT03047330 ↗

“standard treatment with abiraterone acetate, prednisone, and Lupron® (leuprolide) is a safe and effective way to treat previously untreated metastatic prostate cancer” NCT04262154 ↗

“Leuprolide (3.75mg) will be given intramuscularly (in the buttock, thigh, or upper arm) on Day 1 of each cycle x 4 cycles. (Other Names: Leuprorelin, Lupron, Eligard)” NCT03573648 ↗

“All patients will receive luteinizing hormone-releasing hormone (LHRH) agonist therapy (leuprolide or goserelin acetate) concurrent with Cabazitaxel, before surgery.” NCT01531205 ↗

“1-month GnRH (goserelin 3.6 mg depot or goserelin 3.6 mg implant or leuprolide 3.75 mg depot) +endocrine therapy (aromatase inhibitor/tamoxifen±CDK4/6 inhibition)” NCT07610733 ↗

“we propose a randomized clinical trial using one versus three-month Leuprolide preparations in patients otherwise suitable for our Brachytherapy Program.” NCT00175383 ↗

“Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.” NCT01603420 ↗

“Androgen deprivation therapy includes available GnRH agonists and antagonists, such as Triptorelin, Leuprolide, Goserelin and Degarelix.” NCT07477626 ↗

“Hypodermic injection of Luteinizing Hormone-Releasing Hormone Analog every 4 weeks including goserelin, leuprolide, triptorelin ect.” NCT04992026 ↗

“Those with OSA will be randomized to receive CPAP or to receive depot leuprolide to suppress ovarian steroid output over 12 weeks” NCT00696111 ↗

“LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration” NCT00528866 ↗

“ADT will include bicalutamide 50 mg PO daily started 1-2 weeks before leuprolide 22.5mg IM or SQ delivered every 3 months x 2.” NCT05100472 ↗

“["Letrozole","Anastrozole","Exemestane","Tamoxifen","Leuprolide, or other LHRH agonist (per investigator discretion)"]” NCT04569747 ↗

“ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.” NCT03511196 ↗

“Drugs, such as goserelin, leuprolide, flutamide, or bicalutamide, may stop the adrenal glands from making androgens.” NCT00103376 ↗

“Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)” NCT00826839 ↗

“gonadotropin-releasing hormone analog (leuprolide, goserelin, or triptorelin as determined by treating physician)” NCT03279250 ↗

“Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months” NCT00004054 ↗

“LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix.” NCT00936390 ↗

“GnRH agonist or antagonist (leuprolide, goserelin, degarelix) administered as per institutional standard.” NCT07313241 ↗

“Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.” NCT05983107 ↗

“Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months.” NCT05879926 ↗

“ADT will be administered via Leuprolide or Degarelix monthly injections or daily Relugolix pills.” NCT07142967 ↗

“Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.” NCT01076335 ↗

“ADT is defined as a GnRH agonist/antagonist (leuprolide, goserelin, degarelix, or relugolix).” NCT05628363 ↗

“GNRH agonist (leuprolide, goserelin, triptorelin) or GNRH antagonist (relugolix, degarelix)” NCT06528210 ↗

“Leuprolide: Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1.” NCT03009981 ↗

“Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable.” NCT04931342 ↗

“single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate” NCT03845751 ↗

“Triptorelin 3,75 mg or Leuprolide 3,75 mg or goserelin 3,6 mg, as injectable.” NCT03944434 ↗

“gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide)” NCT02454543 ↗

“Available drugs include triptorelin, goserelin, leuprolide, digareke ect.” NCT05406999 ↗

“Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months” NCT04126070 ↗

“leuprolide and goserelin are gonadotropin-releasing hormone analogues” NCT00586898 ↗

“leuprolide: 22.5mg given IM every 3 months for a total of 6 months” NCT00776594 ↗

“This includes leuprolide, goserelin, triptorelin, and degarelix.” NCT02972060 ↗

“Leuprolide 45mg every 6 months for a total of 18 months” NCT02229734 ↗

“Subcutaneous injection of 50 mg Leuprolide Mesylate” NCT02712320 ↗

“leuprolide, goserelin, buserelin, or triptorelin” NCT01492972 ↗

“Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m” NCT02221999 ↗

“Leuprolide is the name of the ADT / IHT drug.” NCT02811809 ↗

“leuprolide, goserelin, triptorelin acetate” NCT04181203 ↗

“Leuprolide” NCT04293393 ↗

“Leuprolide” NCT07596212 ↗

“Leuprolide” NCT05498272 ↗

“Leuprolide” NCT05700903 ↗

“Leuprolide” NCT00329043 ↗

“Leuprolide” NCT06734130 ↗

“Leuprolide” NCT05189457 ↗

NCT01547299 ↗

NCT01546987 ↗

NCT01415960 ↗

NCT02319837 ↗

NCT03261999 ↗

NCT05493709 ↗

NCT00521781 ↗

NCT00161421 ↗

NCT00002582 ↗

NCT00514917 ↗

NCT01338987 ↗

NCT00003394 ↗

NCT01160328 ↗

NCT01023061 ↗

NCT03070886 ↗

NCT00002580 ↗

NCT01161563 ↗

NCT04760691 ↗

NCT00076531 ↗

NCT00076440 ↗

NCT00229996 ↗

NCT02344550 ↗

NCT02914158 ↗

NCT06449027 ↗

NCT01343368 ↗

NCT02269072 ↗

NCT01344564 ↗

NCT00631527 ↗

NCT02458716 ↗

NCT04787744 ↗

NCT00167648 ↗

NCT00455689 ↗

NCT00505817 ↗

NCT00001259 ↗

NCT00653757 ↗

NCT02941926 ↗

NCT00598312 ↗

NCT02663908 ↗

NCT00928434 ↗

NCT01921166 ↗

NCT01762943 ↗

NCT00500110 ↗

NCT01422096 ↗

NCT00438217 ↗

NCT05765500 ↗

NCT01116401 ↗

NCT00587431 ↗

NCT02990845 ↗

NCT06225284 ↗

NCT00454571 ↗

NCT06330805 ↗

NCT00004426 ↗

NCT05212857 ↗

NCT00223665 ↗

NCT00004436 ↗

NCT00541047 ↗

NCT00924469 ↗

NCT00004438 ↗

NCT05096065 ↗

NCT04513717 ↗

NCT02974270 ↗

NCT00388804 ↗

NCT03035032 ↗

NCT01424618 ↗

NCT02069808 ↗

NCT00123110 ↗

NCT02772588 ↗

NCT05924256 ↗

NCT00028769 ↗

NCT03298087 ↗

NCT00026377 ↗

NCT00254397 ↗

NCT05050084 ↗

NCT06397703 ↗

NCT04194554 ↗

NCT00567580 ↗

NCT05320406 ↗

NCT01269125 ↗

NCT00004763 ↗

NCT02262416 ↗

NCT00004771 ↗

NCT02543255 ↗

NCT00002881 ↗

NCT00903162 ↗

NCT04445025 ↗

NCT00128531 ↗

NCT00451958 ↗

NCT02064036 ↗

NCT01642186 ↗

NCT06145438 ↗

NCT00295750 ↗

NCT07455903 ↗

NCT02807363 ↗

NCT06145308 ↗

NCT06984159 ↗

NCT05827081 ↗

NCT07158021 ↗

NCT03056755 ↗

NCT02234115 ↗

NCT07268794 ↗

NCT02158845 ↗

NCT01750398 ↗

NCT02508636 ↗

NCT00244920 ↗

NCT02903368 ↗

NCT06378866 ↗

NCT00684905 ↗

NCT01377389 ↗

NCT00016913 ↗

NCT00003124 ↗

NCT06650579 ↗
Known as CAMCEVI “Leuprolide Injectable Emulsion (CAMCEVI®)” NCT06984159 ↗
Known as CKD-841 “CKD-841(=leuprorelin acetate 3.75mg)” NCT03233932 ↗
1

NCT03233932 ↗
Known as CKD-841 A-1 “CKD-841 A-1(=leuprorelin acetate 3.75mg)” NCT04840745 ↗
Known as CKD-841 D “CKD-841 D(=leuprorelin acetate 2.92mg)” NCT04840745 ↗
Known as Daronda depot “The first group (Group A) was consisted of 60 women who received a depot preparation of a GnRH-a, 3.75 mg s.c, (leuprolide, Daronda depot, 3.75, Abbott, Hellas) every 28 days...” NCT01269125 ↗
Known as Depo-Eligard ClinicalTrials.gov intervention name — accepted as the source's own label NCT06282588 ↗
Known as DKF-MA102 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06490328 ↗
Known as DWJ108J “This study aims to evaluate the efficacy and safety of DWJ108J (Leuprorelin acetate 11.25 mg) in patients with central precocious puberty.” NCT06025409 ↗
Known as Eligard “To this day, the standard curative treatment for high risk prostate cancer patients is external beam radiation therapy (EBRT) combined with hormonal manipulation (Luteinizing...” NCT02303327 ↗
18

“The LUCINDA Trial is a three-site, phase II, randomized, double-blind, placebo-controlled study of leuprolide acetate (Eligard) in women with Mild Cognitive Impairment or...” NCT03649724 ↗

“Patients will continue on ADT with LHRH agonist (i.e. Zoladex, Trelstar, Eligard, or Lupron) or LHRH antagonist (Degarelix or Relugolix) if not surgically castrated throughout...” NCT06922318 ↗

“Patients received two subcutaneous injections of Eligard® 45 mg (leuprorelin acetate), with the first injection given at baseline (Visit 1) and the second after 168 ± 3 days at Visit 4.” NCT05304169 ↗

“Choice of LHRHa per investigator discretion/site practice guidelines (e.g, Eligard®, Zoladex®, Lupron Depot®, Trelstar®) and ARN-509 Tablets, 240 mg/day administered orally” NCT01790126 ↗

“luteinizing hormone-releasing hormone (LHRH) agonist (i.e. Zoladex, Trelstar, Eligard, or Lupron) or LHRH antagonist (Degarelix or Relugolix)” NCT06059118 ↗

“Polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) injected subcutaneously in upper or mid-abdominal area.” NCT01161563 ↗

“LHRH agonist or antagonist (e.g. Eligard, Zoladex, Lupron, Orgovyx)” NCT07142551 ↗

“Leuprolide acetate ( ELIGARD®) Hormonal Therapy” NCT00283062 ↗

“Leuprolide Acetate (Eligard®)” NCT00452556 ↗

“Eligard™” NCT03809000 ↗

“Eligard” NCT03380806 ↗

“Eligard” NCT00005044 ↗

NCT06855589 ↗

NCT02274779 ↗

NCT06654336 ↗

NCT01933022 ↗

NCT04249154 ↗

NCT01511874 ↗
Known as Enantone ClinicalTrials.gov intervention name — accepted as the source's own label NCT05937490 ↗
Known as GnRH-a ClinicalTrials.gov intervention name — accepted as the source's own label NCT02979886 ↗
1

NCT02741154 ↗
Known as GNRH-A Leuprolide Acetate ClinicalTrials.gov intervention name — accepted as the source's own label NCT05617885 ↗
Known as Goserslin “Goserslin” NCT05189457 ↗
Known as LAD “Leuprolide acetate depot (LAD) 11.25 mg 3 Month” NCT00275262 ↗
Known as LEUP “luteinizing hormone-releasing hormone (LHRH) analog (buserelin [BSRL], goserelin [ZDX], or leuprolide [LEUP])” NCT00003653 ↗
Known as Leuplin ClinicalTrials.gov intervention name — accepted as the source's own label NCT03664895 ↗
Known as Leuplin DPS “Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty” NCT03316482 ↗
Known as Leuplin Inj. “Leuplin Inj.(=leuprorelin acetate 3.75mg)” NCT04840745 ↗
Known as LeuplinⓡInj “LeuplinⓡInj(=leuprorelin acetate 3.75mg)” NCT03233932 ↗
Known as Leuporelin “Leuporelin” NCT01978873 ↗
Known as leuprolide acetate “Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix...” NCT03311555 ↗
153

“Patients receive multitargeted tyrosine kinase inhibitor PLX3397 orally (PO) twice daily (BID) for 6 months, undergo radiation therapy for 2 months daily (Monday-Friday)...” NCT02472275 ↗

“All subjects will receive androgen deprivation therapy with a LHRH agonist (any LHRH agonist such as leuprolide acetate or goserelin acetate is acceptable) or a LHRH antagonist...” NCT02582749 ↗

“PURPOSE: This clinical trial investigated the effectiveness, pharmacokinetic properties, and safety profile of leuprolide acetate 22.5-mg depot, a new 3-month leuprolide depot...” PMID 30929678 ↗ Feb 2019

“The purpose of the study is to demonstrate the safety and efficacy of Leuprolide Acetate for Injectable Suspension 22.5 mg in reducing serum testosterone to castrate levels in...” NCT00598312 ↗

“A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and...” NCT00099086 ↗

“The LHRH agonist (leuprolide acetate, goserelin acetate, or triptorelin pamoate) will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according...” NCT03332797 ↗

“These dosages are as follows: leuprolide acetate 22.5 mg depot injection x one dose, abiraterone acetate 1000 mg by mouth daily, and belzutifan120 mg administered by mouth once daily.” NCT05574712 ↗

“This project aims to re-purpose the safe and well-tolerated gonadotropin-releasing hormone (GnRH) analogue Leuprolide Acetate for use in Alzheimer's Disease (AD).” NCT03649724 ↗

“either goserelin acetate at 3.6 mg subcutaneously or leuprolide acetate at 7.5 mg intramuscularly monthly for 6 months starting at Day 1 of therapy.” NCT00016913 ↗

“luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.” NCT02217566 ↗

“Drug: leuprolide acetate Other Names: Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months” NCT01712230 ↗

“Patients will also receive androgen deprivation for 18-24 weeks of an LHRH agonist (eg, leuprolide acetate, goserelin acetate).” NCT00430183 ↗

“Participants received 22.5 mg of leuprolide acetate (eligard) by subcutaneous injection at baseline, month 3, 6, 9, 12 and 15.” NCT03035032 ↗

“Polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) injected subcutaneously in upper or mid-abdominal area.” NCT01161563 ↗

“luteinizing hormone-releasing hormone (LHRH) agonist (e.g., leuprolide acetate, goserelin, buserelin, or triptorelin)” NCT00288080 ↗

“leuprolide acetate 0.5 mg twice daily beginning cycle day 3 and continued until day of HCG (Ovidrel) administration” NCT01921166 ↗

“Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)” NCT00826839 ↗

“LHRH agonists may include, but are not limited to, leuprolide acetate, goserelin acetate, or triptorelin pamoate.” NCT04961996 ↗

“for example, leuprolide acetate 22.5mg IM or goserelin acetate 10.8mg SC given every 3 months for 2 doses” NCT01717053 ↗

“Leuprolide Acetate dosed at 7.5mg intramuscular (IM) injections once per month for a total of 9 months.” NCT00223665 ↗

“participants will then be intramuscularly administered depot leuprolide acetate (11.25 mg Lupron®).” NCT04760691 ↗

“Leuprolide Acetate, brand name Tapros 3.75 mg, injected intramuscularly every month for 3 months” NCT06145438 ↗

“Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly” NCT00001259 ↗

“single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate” NCT03845751 ↗

“the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily” NCT03263299 ↗

“treatment for three months with GnRH analog (leuprolide acetate) alone” NCT01769781 ↗

“the gonadotropin-releasing hormone analog (GnRHa) leuprolide acetate” NCT02158845 ↗

“Oocyte maturation will be triggered by 20 iu of leuprolide acetate.” NCT00804960 ↗

“Leuprolide acetate (Lupron Depot®) 3.75-mg intramuscular injection” NCT00455689 ↗

“gonadotrophin releasing hormone agonist 1mg leuprolide acetate” NCT02916173 ↗

“Leuprolide Acetate for Injectable Suspension 22.5 mg” NCT00076531 ↗

“leuprolide acetate (Lupron Depot, 22.5 mg)” NCT02057939 ↗

“a novel leuprolide acetate 3.75mg depot” NCT03662958 ↗

“Leuprolide acetate, 3 mo depot once” NCT01344564 ↗

“Leuprolide acetate ( Lupron)” NCT03683043 ↗

“45 mg of leuprolide acetate” NCT06926933 ↗

“leuprolide acetate 2 mg SQ” NCT01443546 ↗

“Drug: leuprolide acetate” NCT00026377 ↗

“Drug: Leuprolide Acetate” NCT01762943 ↗

“Drug: Leuprolide Acetate” NCT03070886 ↗

“Drug: leuprolide acetate” NCT00541047 ↗

“leuprolide acetate,” NCT01606709 ↗

“leuprolide acetate” NCT03809000 ↗

NCT03361735 ↗

NCT06305598 ↗

NCT00635817 ↗

NCT02361905 ↗

NCT02361879 ↗

NCT00651326 ↗

NCT00380406 ↗

NCT04484818 ↗

NCT00081159 ↗

NCT01546454 ↗

NCT00512668 ↗

NCT02203331 ↗

NCT02058706 ↗

NCT03544073 ↗

NCT00429494 ↗

NCT01786265 ↗

NCT01163084 ↗

NCT05669664 ↗

NCT00805935 ↗

NCT02770391 ↗

NCT04051320 ↗

NCT00075192 ↗

NCT01120236 ↗

NCT00860158 ↗

NCT02268175 ↗

NCT00004311 ↗

NCT00630799 ↗

NCT02742675 ↗

NCT00734279 ↗

NCT00225420 ↗

NCT00589472 ↗

NCT00937768 ↗

NCT01763541 ↗

NCT00003517 ↗

NCT03902951 ↗

NCT00002633 ↗

NCT01634321 ↗

NCT00001322 ↗

NCT00170157 ↗

NCT03695237 ↗

NCT02278185 ↗

NCT03085095 ↗

NCT02064582 ↗

NCT04734730 ↗

NCT00498901 ↗

NCT07650240 ↗

NCT03541928 ↗

NCT00626431 ↗

NCT02592746 ↗

NCT00924807 ↗

NCT03678025 ↗

NCT01674140 ↗

NCT06106932 ↗

NCT03421639 ↗

NCT01257802 ↗

NCT02023463 ↗

NCT00220350 ↗

NCT00220194 ↗

NCT00544830 ↗

NCT04455750 ↗

NCT04423211 ↗

NCT00003645 ↗

NCT02122198 ↗

NCT00003653 ↗

NCT00002889 ↗

NCT00063310 ↗

NCT04192812 ↗

NCT00621179 ↗

NCT00004635 ↗

NCT00943956 ↗

NCT02452931 ↗

NCT04914195 ↗

NCT02107391 ↗

NCT02689921 ↗

NCT00660010 ↗

NCT02716974 ↗

NCT02168062 ↗

NCT02969590 ↗

NCT00452556 ↗

NCT03093272 ↗

NCT03043807 ↗

NCT04585932 ↗

NCT01712763 ↗

NCT06348264 ↗

NCT04094467 ↗

NCT00949962 ↗

NCT04225221 ↗

NCT00056654 ↗

NCT02736435 ↗

NCT03029533 ↗

NCT02114645 ↗

NCT05605964 ↗

NCT00001481 ↗

NCT01194271 ↗

NCT06169124 ↗

NCT05896293 ↗

NCT00771017 ↗

NCT02357563 ↗

NCT02346253 ↗

NCT00349258 ↗

NCT01431391 ↗

NCT02212197 ↗

NCT03951831 ↗

NCT00687739 ↗

NCT00275262 ↗

NCT02685397 ↗

NCT00283062 ↗

NCT02960022 ↗

NCT00667446 ↗

NCT02927392 ↗
Known as Leuprolide acetate ( Lupron) “Leuprolide acetate ( Lupron)” NCT03683043 ↗
1

“leuprolide acetate (Lupron®)” NCT01531205 ↗
Known as Leuprolide Acetate (delayed release) “Leuprolide Acetate (delayed release)” NCT00429494 ↗
Known as Leuprolide Injectable Emulsion “Leuprolide Injectable Emulsion (CAMCEVI®)” NCT06984159 ↗